Periprocedural, Short-Term, and Long-Term Outcomes of Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy : A 20-Year Single-Center Experience
BACKGROUND: Alcohol septal ablation is recommended for hypertrophic obstructive cardiomyopathy patients who had refractory symptoms despite optimal medical treatment. We compared the periprocedural, short-, and long-term clinical outcomes and mortality predictors in hypertrophic obstructive cardiomyopathy patients who underwent alcohol septal ablation.
METHODS: Hypertrophic obstructive cardiomyopathy patients aged ≥18 years (63 females and 71 males) who underwent alcohol septal ablation were included. The primary endpoint was all-cause mortality.
RESULTS: The mean patient age was 60.0 (standard deviation 13.7) years. The median follow-up time was 13 (7.6-18.5) years. During the procedure, 9, 2, and 1 patients developed ventricular fibrillation, remote site myocardial infarction, and pericardial tamponade, respectively, but none died. One patient died during hospitalization. During the long-term follow-up, 17, 5, 20, and 8 patients developed heart failure, myocardial infarction, chronic atrial fibrillation, and non-fatal stroke, respectively, and 24 died. There was no significant difference between the sexes (all P > .05). Age (hazard ratio=0.69, 95% CI=0.61‒0.78, P < .001), body mass index (hazard ratio=1.20, 95% CI=1.04-1.40, P=.01), age at diagnosis (hazard ratio=1.57, 95% CI=1.34-1.78, P < .001), and time from diagnosis to ablation (hazard ratio=1.57, 95% CI=1.35-1.84, P< .001) predicted all-cause mortality. In Kaplan‒Meier curves, long-term all-cause mortality was similar in men and women (P[log-rank]=.43).
CONCLUSION: Alcohol septal ablation has similar short- and long-term outcomes for both sexes in hypertrophic obstructive cardiomyopathy patients. Risk factors for longterm mortality were age, body mass index, diagnosis age, and time delay to operation. Therefore, alcohol septal ablation timing is essential for better clinical outcomes. Our findings may contribute to the increased performance of alcohol septal ablation in hypertrophic obstructive cardiomyopathy patients in our country.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Anatolian journal of cardiology - 26(2022), 4 vom: 30. Apr., Seite 316-324 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karabulut, Umut [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.04.2022 Date Revised 27.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5152/AnatolJCardiol.2022.852 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339652578 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339652578 | ||
| 003 | DE-627 | ||
| 005 | 20231226003357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5152/AnatolJCardiol.2022.852 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM339652578 | ||
| 035 | |a (NLM)35435843 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karabulut, Umut |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Periprocedural, Short-Term, and Long-Term Outcomes of Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy |b A 20-Year Single-Center Experience |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2022 | ||
| 500 | |a Date Revised 27.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Alcohol septal ablation is recommended for hypertrophic obstructive cardiomyopathy patients who had refractory symptoms despite optimal medical treatment. We compared the periprocedural, short-, and long-term clinical outcomes and mortality predictors in hypertrophic obstructive cardiomyopathy patients who underwent alcohol septal ablation | ||
| 520 | |a METHODS: Hypertrophic obstructive cardiomyopathy patients aged ≥18 years (63 females and 71 males) who underwent alcohol septal ablation were included. The primary endpoint was all-cause mortality | ||
| 520 | |a RESULTS: The mean patient age was 60.0 (standard deviation 13.7) years. The median follow-up time was 13 (7.6-18.5) years. During the procedure, 9, 2, and 1 patients developed ventricular fibrillation, remote site myocardial infarction, and pericardial tamponade, respectively, but none died. One patient died during hospitalization. During the long-term follow-up, 17, 5, 20, and 8 patients developed heart failure, myocardial infarction, chronic atrial fibrillation, and non-fatal stroke, respectively, and 24 died. There was no significant difference between the sexes (all P > .05). Age (hazard ratio=0.69, 95% CI=0.61‒0.78, P < .001), body mass index (hazard ratio=1.20, 95% CI=1.04-1.40, P=.01), age at diagnosis (hazard ratio=1.57, 95% CI=1.34-1.78, P < .001), and time from diagnosis to ablation (hazard ratio=1.57, 95% CI=1.35-1.84, P< .001) predicted all-cause mortality. In Kaplan‒Meier curves, long-term all-cause mortality was similar in men and women (P[log-rank]=.43) | ||
| 520 | |a CONCLUSION: Alcohol septal ablation has similar short- and long-term outcomes for both sexes in hypertrophic obstructive cardiomyopathy patients. Risk factors for longterm mortality were age, body mass index, diagnosis age, and time delay to operation. Therefore, alcohol septal ablation timing is essential for better clinical outcomes. Our findings may contribute to the increased performance of alcohol septal ablation in hypertrophic obstructive cardiomyopathy patients in our country | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Ethanol |2 NLM | |
| 650 | 7 | |a 3K9958V90M |2 NLM | |
| 700 | 1 | |a Yılmaz Can, Yeşim |e verfasserin |4 aut | |
| 700 | 1 | |a Duygu, Egemen |e verfasserin |4 aut | |
| 700 | 1 | |a Karabulut, Dilay |e verfasserin |4 aut | |
| 700 | 1 | |a Keskin, Kudret |e verfasserin |4 aut | |
| 700 | 1 | |a Okay, Tuğrul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anatolian journal of cardiology |d 2014 |g 26(2022), 4 vom: 30. Apr., Seite 316-324 |w (DE-627)NLM239682068 |x 2149-2271 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:4 |g day:30 |g month:04 |g pages:316-324 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5152/AnatolJCardiol.2022.852 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 4 |b 30 |c 04 |h 316-324 | ||